Epidemiology and Risk Factors for the Development of Infectious Complications in Newly Diagnosed Multiple Myeloma: A Multicenter Prospective Cohort Study in Latin America

被引:4
作者
Bove, Virginia [1 ]
Riva, Eloisa [2 ]
Vasquez, Jule [3 ]
Pena, Camila [4 ]
Seehaus, Cristian [5 ]
Samanez, Cesar [6 ]
Bustos, Justina [7 ]
Hernandez, Marcos [8 ]
Fernandez, Julio [9 ]
Rios, Oliday [10 ]
Rodriguez, Yusaima [10 ]
Figueredo, Irving [11 ]
Fantl, Dorotea [5 ]
Malpica, Luis [12 ]
机构
[1] Hosp Cent Ias FF AA, Dept Hematol, Montevideo, Uruguay
[2] Hosp Clin Montevideo, Dept Hematol, Montevideo, Uruguay
[3] Inst Nacl Enfermedades Neoplas, Dept Med Oncol, Lima, Peru
[4] Hosp Salvador, Dept Hematol, Santiago, Chile
[5] Hosp Italiano Buenos Aires, Dept Hematol, Buenos Aires, Argentina
[6] Oncosalud AUNA, Dept Med Oncol, Lima, Peru
[7] Inst Oncol Nacl, Dept Hematol & Bone Marrow Transplantat, Panama City, Panama
[8] Univ Carabobo, Hosp Metropolitano Norte, Dept Hematol, Valencia, Venezuela
[9] Hosp Gen Univ Dr Gustavo Aldereguia Lima, Dept Hematol, Cienfuegos, Cuba
[10] Hosp Hermanos Ameijeiras, Dept Hematol, Havana, Cuba
[11] Ctr Invest Med Quirurg, Dept Hematol, Havana, Cuba
[12] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX USA
关键词
BACTERIAL-INFECTION; ERA; LENALIDOMIDE; PROPHYLAXIS; VACCINATION; MANAGEMENT; MORTALITY;
D O I
10.1200/GO.22.00068
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PURPOSEInfections are a significant cause of morbidity and mortality in patients with multiple myeloma (MM). In Latin America, data on infectious complications in this patient population are lacking. METHODS We conducted a prospective cohort study of patients with newly diagnosed MM (NDMM) in seven Latin American countries between June 2019 and May 2020. Patients with active disease, on active therapy, and with a follow-up of 6 months from the time of diagnosis were included. Our primary end point was the number of infectious events that required hospitalization for >= 24 hours. RESULTS Of 248 patients with NDMM, 89 (35.9%) had infectious complications (113 infectious events), the majority (67.3%) within the first 3 months from diagnosis. The most common sites of infection were respiratory (38%) and urinary tract (31%). The microbial agent was identified in 57.5% of patients with gram-negative bacteria (73.5%) as the most common pathogen. Viral infections were infrequent, and no patients with fungal infection were reported. In the multivariable analysis, diabetes mellitus (odds ratio [OR], 2.71; 95% CI, 1.23 to 6.00; P = .014), creatinine >= 2 mg/dL (OR, 4.87; 95% CI, 2.29 to 10.35; P < .001), no use of trimethoprim-sulfamethoxazole prophylaxis (OR, 6.66; 95% CI, 3.43 to 12.92; P < .001), and treatment with immunomodulatory drugs (OR, 3.02; 95% CI, 1.24 to 6.29; P = .003) were independent factors associated with bacterial infections. At 6 months, 21 patients (8.5%) had died, 47.6% related to infectious complications. CONCLUSION Bacterial infections are a substantial cause of hospital admissions and early death in patients with NDMM. Antibiotic prophylaxis should be considered to reduce infectious complications in patients with MM.
引用
收藏
页数:10
相关论文
共 39 条
[1]   Early mortality after diagnosis of multiple myeloma: Analysis of patients entered onto the United Kingdom Medical Research Council trials between 1980 and 2002 - Medical Research Council Adult Leukaemia Working Party [J].
Augustson, BM ;
Begum, G ;
Dunn, JA ;
Barth, NJ ;
Davies, F ;
Morgan, G ;
Behrens, J ;
Smith, A ;
Child, JA ;
Drayson, MT .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (36) :9219-9226
[2]   Renal, hematologic and infectious complications in multiple myeloma [J].
Bladé, J ;
Rosiñol, L .
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2005, 18 (04) :635-652
[3]   Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients [J].
Blimark, Cecilie ;
Holmberg, Erik ;
Mellqvist, Ulf-Henrik ;
Landgren, Ola ;
Bjoekholm, Magnus ;
Hultcrantz, Malin ;
Kjellander, Christian ;
Turesson, Ingemar ;
Kristinsson, Sigurdur Y. .
HAEMATOLOGICA, 2015, 100 (01) :107-113
[4]   The risk of infections in multiple myeloma before and after the advent of novel agents: a 12-year survey [J].
Brioli, Annamaria ;
Klaus, Maximilian ;
Sayer, Herbert ;
Scholl, Sebastian ;
Ernst, Thomas ;
Hilgendorf, Inken ;
Scherag, Andre ;
Yomade, Olaposi ;
Schilling, Kristina ;
Hochhaus, Andreas ;
Muegge, Lars-Olof ;
von Lilienfeld-Toal, Marie .
ANNALS OF HEMATOLOGY, 2019, 98 (03) :713-722
[5]   Infection complications in an unselected cohort of patients with multiple myeloma treated with lenalidomide combinations [J].
Caravita, Tommaso ;
Offidani, Massimo ;
Siniscalchi, Agostina ;
Gentili, Silvia ;
Caraffa, Patrizia ;
Perrotti, Alessio ;
de Fabritiis, Paolo ;
Leoni, Pietro .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2012, 89 (03) :276-277
[6]   Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study [J].
Chanan-Khan, Asher ;
Sonneveld, Pieter ;
Schuster, Michael W. ;
Stadtmauer, Edward A. ;
Facon, Thierry ;
Harousseau, Jean-Luc ;
Ben-Yehuda, Dina ;
Lonial, Sagar ;
Goldschmidt, Hartmut ;
Reece, Donna ;
Neuwirth, Rachel ;
Anderson, Kenneth C. ;
Richardson, Paul G. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (29) :4784-4790
[7]   Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis [J].
Chen, Nionhang ;
Lau, Henry ;
Kon, Linghui ;
Kumar, Gondi ;
Zeldis, Jerome B. ;
Knight, Robert ;
Laskin, Oscar L. .
JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 47 (12) :1466-1475
[8]   Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial [J].
Drayson, Mark T. ;
Bowcock, Stella ;
Planche, Tim ;
Iqbal, Gulnaz ;
Pratt, Guy ;
Yong, Kwee ;
Wood, Jill ;
Raynes, Kerry ;
Higgins, Helen ;
Dawkins, Bryony ;
Meads, David ;
Hulme, Claire T. ;
Monahan, Irene ;
Karunanithi, Kamaraj ;
Dignum, Helen ;
Belsham, Edward ;
Neilson, Jeff ;
Harrison, Beth ;
Lokare, Anand ;
Campbell, Gavin ;
Hamblin, Michael ;
Hawkey, Peter ;
Whittaker, Anna C. ;
Low, Eric ;
Dunn, Janet A. .
LANCET ONCOLOGY, 2019, 20 (12) :1760-1772
[9]   A predictive model for risk of early grade ≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial [J].
Dumontet, Charles ;
Hulin, Cyrille ;
Dimopoulos, Meletios A. ;
Belch, Andrew ;
Dispenzieri, Angela ;
Ludwig, Heinz ;
Rodon, Philippe ;
Van Droogenbroeck, Jan ;
Qiu, Lugui ;
Cavo, Michele ;
Van de Velde, Ann ;
Lahuerta, Juan Jose ;
Allangba, Olivier ;
Lee, Jae Hoon ;
Boyle, Eileen ;
Perrot, Aurore ;
Moreau, Philippe ;
Manier, Salomon ;
Attal, Michel ;
Roussel, Murielle ;
Mohty, Mohamad ;
Mary, Jean Yves ;
Civet, Alexandre ;
Costa, Bruno ;
Tinel, Antoine ;
Gaston-Mathe, Yann ;
Facon, Thierry .
LEUKEMIA, 2018, 32 (06) :1404-1413
[10]   Management of infectious complications in multiple myeloma patients: Expert panel consensus-based recommendations [J].
Girmenia, Corrado ;
Cavo, Michele ;
Offidani, Massimo ;
Scaglione, Francesco ;
Corso, Alessandro ;
Di Raimondo, Francesco ;
Musto, Pellegrino ;
Petrucci, Maria Teresa ;
Barosi, Giovanni .
BLOOD REVIEWS, 2019, 34 :84-94